

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Riluzole Zentiva 50 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 50 mg of riluzole.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet

The tablets are capsule-shaped, white and engraved with “RPR 202” on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).

Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS (see section 5.1). Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.

There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole Zentiva has not been shown to be effective in the late stages of ALS.

Safety and efficacy of Riluzole Zentiva has only been studied in ALS. Therefore, Riluzole Zentiva should not be used in patients with any other form of motor neurone disease.

4.2 Posology and method of administration

Treatment with Riluzole Zentiva should only be initiated by specialist physicians with experience in the management of motor neurone diseases.

Posology

The recommended daily dose in adults or older people is 100 mg (50 mg every 12 hours). No significant increased benefit can be expected from higher daily doses.

Special populations

Renal impairment

Riluzole Zentiva is not recommended for use in patients with impaired renal function, as studies at repeated doses have not been conducted in this population (see section 4.4).

Elderly

Based on pharmacokinetic data, there are no special instructions for the use of Riluzole Zentiva in this population.

Hepatic impairment

See sections 4.3, 4.4 and 5.2

Paediatric population

Riluzole Zentiva is not recommended for use paediatric population, due to a lack of data on the safety and efficacy of riluzole in any neurodegenerative diseases occurring in children or adolescents.

Method of administration

Oral use

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Hepatic disease or baseline transaminases greater than 3 times the upper limit of normal.

Patients who are pregnant or breast-feeding.

4.4 Special warnings and precautions for use

Hepatic impairment

Riluzole should be prescribed with care in patients with a history of abnormal liver function, or in patients with slightly elevated serum transaminases (ALT/SGPT; AST/SGOT up to 3 times the upper limit of the normal range (ULN)), bilirubin and/or gamma-glutamyl transferase (GGT) levels. Baseline elevations of several liver function tests (especially elevated bilirubin) should preclude the use of riluzole (see section 4.8).

Because of the risk of hepatitis, serum transaminases, including ALT, should be measured before and during therapy with riluzole. ALT should be measured every month during the first 3 months of treatment, every 3 months during the remainder of the first year, and periodically thereafter. ALT levels should be measured more frequently in patients who develop elevated ALT levels.

Riluzole should be discontinued if the ALT levels increase to 5 times the ULN. There is no experience with dose reduction or rechallenge in patients who have developed an increase of ALT to 5 times ULN. Readministration of riluzole to patients in this situation cannot be recommended.

Neutropenia

Patients should be warned to report any febrile illness to their physicians. The report of a febrile illness should prompt physicians to check white blood cell counts and to discontinue riluzole in case of neutropenia (see section 4.8).

Interstitial lung disease

Cases of interstitial lung disease have been reported in patients treated with riluzole, some of them were severe (see section 4.8). If respiratory symptoms develop such as dry cough and/or dyspnoea, chest radiography should be performed, and in case of findings suggestive of interstitial lung disease (e.g. bilateral diffuse lung opacities), riluzole should be discontinued immediately. In the majority of the reported cases, symptoms resolved after medicinal product discontinuation and symptomatic treatment.

Renal impairment

Studies at repeated doses have not been conducted in patients with impaired renal function (see section

4.2).

4.5 Interaction with other medicinal products and other forms of interaction

There have been no clinical studies to evaluate the interactions of riluzole with other medicinal products.

In vitro studies using human liver microsomal preparations suggest that CYP 1A2 is the principal isozyme involved in the initial oxidative metabolism of riluzole. Inhibitors of CYP 1A2 (e.g. caffeine, diclofenac, diazepam, nicergoline, clomipramine, imipramine, fluvoxamine, phenacetin, theophylline, amitriptyline and quinolones) could potentially decrease the rate of riluzole elimination, while inducers of CYP 1A2 (e.g. cigarette smoke, charcoal-broiled food, rifampicin and omeprazole) could increase the rate of riluzole elimination.

4.6 Fertility, pregnancy and lactation

Pregnancy

Riluzole Zentiva is contraindicated in pregnancy (see sections 4.3 and 5.3). Clinical experience with riluzole in pregnant women is lacking.

Breast-feeding

Riluzole Zentiva is contraindicated in breast-feeding women (see sections 4.3 and 5.3). It is not known whether riluzole is excreted in human milk.

Fertility

Fertility studies in rats revealed slight impairment of reproductive performance and fertility at doses of 15 mg/kg/day (which is higher than the therapeutic dose), probably due to sedation and lethargy.

4.7 Effects on ability to drive and use machines

Patients should be warned about the potential for dizziness or vertigo, and advised not to drive or operate machinery if these symptoms occur.

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Undesirable effects

Summary of safety profile

In phase III clinical studies conducted in ALS patients treated with riluzole, the most commonly reported adverse reactions were asthenia, nausea and abnormal liver function tests.

Tabulated summary of adverse reactions

Undesirable effects ranked under headings of frequency are listed below, using the following convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), very rare ($< 1/10,000$), not known (cannot be estimated from the available data).

	Very common	Common	Uncommon	Not known
Blood and lymphatic system disorders			Anaemia	Severe neutropenia (see section 4.4)
Immune system disorders			Anaphylactoid reaction, angioedema	
Nervous system disorders		Headache, dizziness, oral paraesthesia, somnolence		
Cardiac disorders		Tachycardia		
Respiratory, thoracic and mediastinal disorders			Interstitial lung disease (see section 4.4)	
Gastrointestinal disorders	Nausea	Diarrhoea, abdominal pain, vomiting	Pancreatitis	
Hepato-biliary disorders	Abnormal liver function tests			Hepatitis
Skin and subcutaneous tissue disorders				Rash
General disorders and administration site conditions	Asthenia	Pain		

Description of selected adverse reactions

Hepato-biliary disorders

Increased alanine aminotransferase usually appeared within 3 months after the start of therapy with riluzole; they were usually transient and levels returned to below twice the ULN after 2 to 6 months while treatment was continued. These increases could be associated with jaundice. In patients (n=20) from clinical studies with increases in ALT to more than 5 times the ULN, treatment was discontinued and the levels returned to less than 2 times the ULN within 2 to 4 months in most cases (see section 4.4)

Study data indicate that Asian patients may be more susceptible to liver function test abnormalities - 3.2% (194/5995) of Asian patients and 1.8% (100/5641) of Caucasian patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

4.9 Overdose

Neurological and psychiatric symptoms, acute toxic encephalopathy with stupor, coma, and methaemoglobinaemia have been observed in isolated cases.

In case of overdose, treatment is symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other nervous system drugs, ATC code: N07XX02.

Mechanism of action

Although the pathogenesis of ALS is not completely elucidated, it is suggested that glutamate (the primary excitatory neurotransmitter in the central nervous system) plays a role for cell death in the disease.

Riluzole is proposed to act by inhibiting glutamate processes. The mode of action is unclear.

Clinical efficacy and safety

In a trial, 155 patients were randomised to riluzole 100 mg/day (50 mg twice daily) or placebo and were followed-up for 12 to 21 months. Survival, as defined in the second paragraph of section 4.1, was significantly extended for patients who received riluzole as compared to patients who received placebo. The median survival time was 17.7 months versus 14.9 months for riluzole and placebo, respectively.

In a dose-ranging trial, 959 patients with ALS were randomised to one of four treatment groups: riluzole 50, 100, 200 mg/day, or placebo and were followed-up for 18 months. In patients treated with riluzole 100 mg/day, survival was significantly higher compared to patients who received placebo. The effect of riluzole 50 mg/day was not statistically significant compared to placebo and the effect of 200 mg/day was essentially comparable to that of 100 mg/day. The median survival time approached 16.5 months versus 13.5 months for riluzole 100 mg/day and placebo, respectively.

In a parallel group study designed to assess the efficacy and safety of riluzole in patients at a late stage of the disease, survival time and motor function under riluzole did not differ significantly from that of placebo. In this study the majority of patients had a vital capacity less than 60%.

In a double-blind placebo-controlled trial designed to assess the efficacy and safety of riluzole in Japanese patients, 204 patients were randomised to riluzole 100 mg/day (50 mg twice daily) or placebo and were followed-up for 18 months. In this study, the efficacy was assessed on inability to walk alone, loss of upper limb function, tracheostomy, need for artificial ventilation, gastric tube feeding or death. Tracheostomy-free survival in patients treated with riluzole did not differ significantly from placebo. However, the power of this study to detect differences between treatment groups was low. Meta-analysis including this study and those described above showed a less striking effect on survival for riluzole as compared to placebo although the differences remained statistically significant.

5.2 Pharmacokinetic properties

The pharmacokinetics of riluzole have been evaluated in healthy male volunteers after single oral administration of 25 to 300 mg and after multiple-dose oral administration of 25 to 100 mg bid. Plasma levels increase linearly with the dose and the pharmacokinetic profile is dose-independent. With multiple dose administration (10 day-treatment at 50 mg riluzole bid), unchanged riluzole accumulates in plasma by about 2 fold and steady-state is reached in less than 5 days.

Absorption

Riluzole is rapidly absorbed after oral administration with maximal plasma concentrations occurring within 60 to 90 minutes ($C_{\max}=173 \pm 72$ (sd) ng/ml). About 90% of the dose is absorbed and the absolute bioavailability is $60 \pm 18\%$.

The rate and extent of absorption is reduced when riluzole is administered with high-fat meals (decrease in C_{\max} of 44%, decrease in AUC of 17%).

Distribution

Riluzole is extensively distributed throughout the body and has been shown to cross the blood brain barrier. The volume of distribution of riluzole is about 245 ± 69 L (3.4 L/kg). Riluzole is about 97% protein bound and it binds mainly to serum albumin and to lipoproteins.

Biotransformation

Unchanged riluzole is the main component in plasma and is extensively metabolised by cytochrome P450 and subsequent glucuronidation. *In vitro* studies using human liver preparations demonstrated that cytochrome P450 1A2 is the principal isoenzyme involved in the metabolism of riluzole. The metabolites identified in urine are three phenolic derivatives, one ureido-derivative and unchanged riluzole.

The primary metabolic pathway for riluzole is initial oxidation by cytochrome P450 1A2 producing N-hydroxy-riluzole (RPR112512), the major active metabolite of riluzole. This metabolite is rapidly glucuronoconjugated to O- and N-glucuronides.

Elimination

The elimination half-life ranges from 9 to 15 hours. Riluzole is eliminated mainly in the urine. The overall urinary excretion accounts for about 90% of the dose. Glucuronides accounted for more than 85% of the metabolites in the urine. Only 2% of a riluzole dose was recovered unchanged in the urine.

Special populations

Renal impairment

There is no significant difference in pharmacokinetic parameters between patients with moderate or severe chronic renal insufficiency (creatinine clearance between 10 and 50 ml.min⁻¹) and healthy volunteers after a single oral dose of 50 mg riluzole.

Elderly

The pharmacokinetic parameters of riluzole after multiple dose administration (4.5 days of treatment at 50 mg riluzole bid) are not affected in the older people (>70 years).

Hepatic impairment

The AUC of riluzole after a single oral dose of 50 mg increases by about 1.7 fold in patients with mild chronic liver insufficiency and by about 3 fold in patients with moderate chronic liver insufficiency.

Race

A clinical study conducted to evaluate the pharmacokinetics of riluzole and its metabolite N-hydroxyriluzole following repeated oral administration twice daily for 8 days in 16 healthy Japanese and 16 Caucasian adult males showed in the Japanese group a lower exposure of riluzole (C_{\max} 0.85 [90% CI 0.68-1.08] and AUC_{inf} 0.88 [90% CI 0.69-1.13]) and similar exposure to the metabolite. The clinical significance of these results is not known.

5.3 Preclinical safety data

Riluzole did not show any carcinogenicity potential in either rats or mice.

Standard tests for genotoxicity performed with riluzole were negative. Tests on the major active metabolite of riluzole gave positive results in two *in vitro* tests. Intensive testing in seven other standard *in vitro* or *in vivo* assays did not show any genotoxic potential of the metabolite. On the basis of these data, and taking into consideration the negative studies on the carcinogenesis of riluzole in the mouse and rat, the genotoxic effect of this metabolite is not considered to be of relevance in humans.

Reductions in red blood cell parameters and/or alterations in liver parameters were noted inconsistently in subacute and chronic toxicity studies in rats and monkeys. In dogs, haemolytic anaemia was observed.

In a single toxicity study, the absence of corpora lutea was noted at a higher incidence in the ovary of treated compared to control female rats. This isolated finding was not noted in any other study or species.

All these findings were noted at doses which were 2-10 times higher than the human dose of 100 mg/day.

In the pregnant rat, the transfer of ¹⁴C-riluzole across the placenta to the foetus has been detected. In rats, riluzole decreased the pregnancy rate and the number of implantations at exposure levels at least twice the systemic exposure of humans given clinical therapy. No malformations were seen in animal reproductive studies.

In lactating rats, ¹⁴C-riluzole was detected in milk.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Core

Dibasic calcium phosphate, anhydrous
Micro crystalline cellulose
Colloidal silica, anhydrous
Magnesium stearate
Croscarmellose sodium

Coating

Hypromellose
Macrogol 6000
Titanium dioxide (E171)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Tablets are packaged in opaque pvc/aluminium blister cards.

Each package contains 28, 56, 98, 112 or 168 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Zentiva k.s.

U kabelovny 130

102 37 Prague 10

Czech Republic

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/768/001

EU/1/12/768/002

EU/1/12/768/003

EU/1/12/768/004

EU/1/12/768/005

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 07 May 2012

Date of latest renewal: 09 January 2017

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

ANNEX II

- A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers responsible for batch release

Opella Healthcare International SAS
56, Route de Choisy
60200 Compiègne
France

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- **Periodic Safety Update Reports**

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- **Risk Management Plan (RMP)**

Not applicable

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Riluzole Zentiva 50 mg film-coated tablets
riluzole

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 50 mg of riluzole.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

56 film-coated tablets
28 film-coated tablets
98 film-coated tablets
112 film-coated tablets
168 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Zentiva k.s.
U kabelovny 130
102 37 Prague 10
Czech Republic

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/768/001 – 56 film-coated tablets
EU/1/12/768/002 – 28 film-coated tablets
EU/1/12/768/003 – 98 film-coated tablets
EU/1/12/768/004 – 112 film-coated tablets
EU/1/12/768/005 – 168 film-coated tablets

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Riluzole Zentiva

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

PVC/ALUMINIUM BLISTER

1. NAME OF THE MEDICINAL PRODUCT

Riluzole Zentiva 50 mg film-coated tablets
riluzole

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Zentiva k.s.

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Batch

5. OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the user

Riluzole Zentiva 50 mg film-coated tablets riluzole

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Riluzole Zentiva is and what it is used for
2. What you need to know before you take Riluzole Zentiva
3. How to take Riluzole Zentiva
4. Possible side effects
5. How to store Riluzole Zentiva
6. Contents of the pack and other information

1. What Riluzole Zentiva is and what it is used for

What Riluzole Zentiva is

The active substance in Riluzole Zentiva is riluzole which acts on the nervous system.

What Riluzole Zentiva is used for

Riluzole Zentiva is used in patients with amyotrophic lateral sclerosis (ALS).

ALS is a form of motor neurone disease where attacks of the nerve cells responsible for sending instructions to the muscles lead to weakness, muscle waste and paralysis.

The destruction of nerve cells in motor neurone disease may be caused by too much glutamate (a chemical messenger) in the brain and spinal cord. Riluzole Zentiva stops the release of glutamate and this may help in preventing the nerve cells being damaged.

Please consult your doctor for more information about ALS and the reason why this medicine has been prescribed for you.

2. What you need to know before you take Riluzole Zentiva

Do not take Riluzole Zentiva

- if you are **allergic** to riluzole or any of the other ingredients of this medicine (listed in section 6),
- if you have any **liver disease** or increased blood levels of some enzymes of the liver (transaminases),
- if you are **pregnant or breast-feeding**.

Warnings and precautions

Talk to your doctor before taking Riluzole Zentiva:

- if you have any **liver problems**: yellowing of your skin or the white of your eyes (jaundice), itching all over, feeling sick, being sick
- if your **kidneys** are not working very well
- if you have any **fever**: it may be due to a low number of white blood cells which can cause an increased risk of infection

If any of the above applies to you, or if you are not sure, tell your doctor who will decide what to do.

Children and adolescents

If you are less than 18 years of age, the use of Riluzole Zentiva is not recommended because there is no information available in this population.

Other medicines and Riluzole Zentiva

Tell your doctor if you are taking, have recently taken or might take any other medicines.

Pregnancy, breast-feeding and fertility

You **MUST NOT** take Riluzole Zentiva if you are or think you may be pregnant, or if you are breast-feeding.

If you think you may be pregnant, or if you intend to breast-feed, ask your doctor for advice before taking Riluzole Zentiva.

Driving and using machines

You can drive or use any tools or machines, unless you feel dizzy or light headed after taking this medicine.

3. How to take Riluzole Zentiva

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is one tablet, twice a day.

The tablets should be taken by mouth, every 12 hours, at the same time of the day each day (e.g. in the morning and evening).

If you take more Riluzole Zentiva than you should

If you take too many tablets, contact your doctor or the nearest hospital emergency department immediately.

If you forget to take Riluzole Zentiva

If you forget to take your tablet, leave out that dose completely and take the next tablet at the usual time.

Do not take a double dose to make up for a forgotten tablet.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

IMPORTANT

Tell your doctor immediately

- if you experience any **fever** (increase in temperature) because Riluzole Zentiva may cause a decrease in the number of white blood cells. Your doctor may want to take a blood sample to check the number of white blood cells, which are important in fighting infections.
- if you experience any of the following symptoms: yellowing of your skin or the white of your eyes (jaundice), itching all over, feeling sick, being sick, as this may be signs of **liver disease** (hepatitis). Your doctor may do regular blood tests while you are taking Riluzole Zentiva to make sure that this does not occur.
- if you experience cough or difficulties in breathing, as this may be a sign of lung disease (called interstitial lung disease).

Other side effects

Very common side effects (may affect more than 1 in 10 people) of Riluzole Zentiva are:

- tiredness
- feeling sick
- increased blood levels of some enzymes of the liver (transaminases).

Common side effects (may affect up to 1 in 10 people) of Riluzole Zentiva are:

- | | | |
|--------------|-------------------------------------|-------------|
| - dizziness | - numbness or tingling of the mouth | - vomiting |
| - sleepiness | - increase in heart beat | - diarrhoea |
| - headache | - abdominal pain | - pain |

Uncommon side effects (may affect up to 1 in 100 people) of Riluzole Zentiva are:

- anaemia
- allergic reactions
- inflammation of the pancreas (pancreatitis).

Not known effects (frequency cannot be estimated from the available data) of Riluzole Zentiva are:

- rash

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Riluzole Zentiva

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

6. Contents of the pack and other information

What Riluzole Zentiva contains

- The active substance is riluzole.
- The other ingredients are:

Core: anhydrous dibasic calcium phosphate, micro crystalline cellulose, anhydrous colloidal silica, magnesium stearate, croscarmellose sodium;

Coating: hypromellose, macrogol 6000, titanium dioxide (E171).

What Riluzole Zentiva looks like and content of the pack

The tablets are film-coated, capsule-shaped and white. Each tablet contains 50 mg of riluzole and is engraved with “RPR 202” on one side.

Riluzole Zentiva is available in a pack of 28, 56, 98, 112 or 168 tablets to be taken orally.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Zentiva k.s.

U kabelovny 130

102 37 Prague 10

Czech Republic

Manufacturers

Opella Healthcare International SAS

56, Route de Choisy

60200 Compiègne

France

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

Zentiva, k.s.

Tél/Tel: +32 (78) 700 112

PV-Belgium@zentiva.com

Lietuva

Zentiva, k.s.

Tel: +370 52152025

PV-Lithuania@zentiva.com

България

Zentiva, k.s.

Тел: +35924417136

PV-Bulgaria@zentiva.com

Luxembourg/Luxemburg

Zentiva, k.s.

Tél/Tel: +352 208 82330

PV-Luxembourg@zentiva.com

Česká republika

Zentiva, k.s.

Tel: +420 267 241 111

PV-Czech-Republic@zentiva.com

Magyarország

Zentiva Pharma Kft.

Tel.: +36 1 299 1058

PV-Hungary@zentiva.com

Danmark

Zentiva Denmark ApS

Tlf: +45 787 68 400

PV-Denmark@zentiva.com

Malta

Zentiva, k.s.

Tel: +356 2034 1796

PV-Malta@zentiva.com

Deutschland

Zentiva Pharma GmbH
Tel: +49 (0) 800 53 53 010
PV-Germany@zentiva.com

Eesti

Zentiva, k.s.
Tel: +372 52 70308
PV-Estonia@zentiva.com

Ελλάδα

Zentiva, k.s.
Τηλ: +30 211 198 7510
PV-Greece@zentiva.com

España

Zentiva, k.s.
Tel: +34 671 365 828
PV-Spain@zentiva.com

France

Zentiva France
Tél: +33 (0) 800 089 219
PV-France@zentiva.com

Hrvatska

Zentiva d. o. o.
Tel: +385 1 6641 830
PV-Croatia@zentiva.com

Ireland

Zentiva, k.s.
Tel: +353 818 882 243
PV-Ireland@zentiva.com

Ísland

Zentiva Denmark ApS
Sími: +354 539 5025
PV-Iceland@zentiva.com

Italia

Zentiva Italia S.r.l.
Tel: +39 800081631
PV-Italy@zentiva.com

Κύπρος

Zentiva, k.s.
Τηλ: +30 211 198 7510
PV-Cyprus@zentiva.com

Latvija

Zentiva, k.s.
Tel: +371 67893939
PV-Latvia@zentiva.com

Nederland

Zentiva, k.s.
Tel: +31 202 253 638
PV-Netherlands@zentiva.com

Norge

Zentiva Denmark ApS
Tlf: +45 787 68 400
PV-Norway@zentiva.com

Österreich

Zentiva, k.s.
Tel: +43 720 778 877
PV-Austria@zentiva.com

Polska

Zentiva Polska Sp. z o.o.
Tel: + 48 22 375 92 00
PV-Poland@zentiva.com

Portugal

Zentiva Portugal, Lda
Tel: +351210601360
PV-Portugal@zentiva.com

România

ZENTIVA S.A.
Tel: +4 021.304.7597
PV-Romania@zentiva.com

Slovenija

Zentiva, k.s.
Tel: +386 360 00 408
PV-Slovenia@zentiva.com

Slovenská republika

Zentiva, a.s.
Tel: +421 2 3918 3010
PV-Slovakia@zentiva.com

Suomi/Finland

Zentiva Denmark ApS
Puh/Tel: +358 942 598 648
PV-Finland@zentiva.com

Sverige

Zentiva Denmark ApS
Tel: +46 840 838 822
PV-Sweden@zentiva.com

This leaflet was last revised in <Month YYYY>.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: <https://www.ema.europa.eu>.